SUPPORTING MATERIALS +

CONTACT US

Oncology

CALENDAR

HOME

HOME > ONCOLOGY

Welcome to Janssen Medical Cloud — Oncology

PORTFOLIO ▼

Janssen Medical Cloud Oncology is a platform that provides you as a healthcare professional with relevant and useful information in the field of uro-oncology, and more specifically with regard to prostate cancer.

This professional platform gives you easy access to our online and offline medical education programs, which include the most recent updates from the major conferences within your field (ASCO, ASCO-GU, ESMO, EAU, APCCC).

In addition, you can access our clinical trials and the Janssen oncology portfolio from this resource with ease — including all supporting scientific studies and useful materials for your patients.

Calendar

Janssen follows the medical news closely and curates an interesting program of both online and offline scientific symposiums for your benefit.

Prostate cancer (PC)

Urothelial cell carcinoma (UC)



ASCO GU LIVE MEETINGTM

February 12-13, 2021



News

Now reimbursed in Luxembourg

ERLEADA (APALUTAMIDE) NOW REIMBURSED IN LUXEMBOURG

From July 2020, ERLEADA® will be reimbursed in Luxembourg (national no. 0885824) in adult men for the treatment of:

- non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of developing metastatic disease
- metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

FIND OUT MORE >

Resources to discover

Portfolio Consult practical information about Janssen Oncology, find out about our registration studies, current clinical studies and more. FIND OUT MORE \rightarrow



PubMed Are you looking for a recent article and bibliographical references relating to a particular topic in your field? Then we would be happy to help you — with a publication from the extensive PubMed database.

Contact us, we are happy to help

CONTACT US>

References

*PSA: Prostate-Specific Antigen

1. https://www.who.int/news-room/detail/09-07-2019-who-updates-global-guidance-on-medicines-and-diagnostic-tests-to-address-health-challenges-prioritize-highlyeffective-therapeutics-and-improve-affordable-access

CP-183545 - 06-Oct-2020

Cookie Settings

YOU CAN FOLLOW US ON y 0 f

CONTACT US

CONTACT US

Privacybeleid C Gebruikersvoorwaarden Terms & conditions

© Janssen-Cilag NV – PHBE/JAN/0317/0002 - Laatst aangepast op: 1 januari 2020. Deze site wordt onderhouden door Janssen-Cilag NV die als enige verantwoordelijk is voor de inhoud. Deze website is bedoeld voor Healthcare Professionals uit België en G.H. Luxemburg. Door op onze site te surfen, verklaart u zich akkoord met onze Juridische kennisgeving, ons Privacybeleid Zen Cookiebeleid.

